Suppliers and packagers for generic pharmaceutical drug: TERIPARATIDE

TERIPARATIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alvogen	BONSITY	teriparatide	SOLUTION;SUBCUTANEOUS	211939	NDA	Alvogen, Inc.	47781-652-89	1 SYRINGE in 1 CARTON (47781-652-89) / 2.24 mL in 1 SYRINGE	2019-11-14
Alvogen	BONSITY	teriparatide	SOLUTION;SUBCUTANEOUS	211939	NDA	Alvogen Inc.	47781-852-89	1 SYRINGE in 1 CARTON (47781-852-89) / 2.24 mL in 1 SYRINGE	2025-06-06
Lilly	FORTEO	teriparatide	SOLUTION;SUBCUTANEOUS	021318	NDA	Eli Lilly and Company	0002-8400-01	1 SYRINGE in 1 CARTON (0002-8400-01) / 2.24 mL in 1 SYRINGE	2002-11-26
Lilly	FORTEO	teriparatide	SOLUTION;SUBCUTANEOUS	021318	NDA	Eli Lilly and Company	0002-9678-01	1 SYRINGE in 1 CARTON (0002-9678-01) / 2.24 mL in 1 SYRINGE	2025-06-03
Lilly	FORTEO	teriparatide	SOLUTION;SUBCUTANEOUS	021318	NDA AUTHORIZED GENERIC	Prasco Laboratories	66993-495-28	1 SYRINGE in 1 CARTON (66993-495-28) / 2.24 mL in 1 SYRINGE	2023-11-17

Teriparatide Drug Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the supplier landscape for teriparatide, a parathyroid hormone analog used for osteoporosis treatment. Key suppliers include Active Pharmaceutical Ingredient (API) manufacturers and Finished Dosage Form (FDF) contract manufacturers. Market intelligence indicates concentrated API production, primarily in Asia, with established players holding significant market share. FDF manufacturing demonstrates a more diversified base, including both specialized biopharmaceutical CMOs and larger contract manufacturers with broad capabilities. The competitive landscape is influenced by patent expiry for originator products and the emergence of biosimilar manufacturers.

What are the Key Active Pharmaceutical Ingredient (API) Suppliers for Teriparatide?

The production of teriparatide API is dominated by a limited number of manufacturers. These companies possess the specialized expertise and regulatory approvals required for complex peptide synthesis.

• Key API Manufacturers:

  • Bachem AG: A prominent Swiss peptide manufacturer with extensive experience in API production for biopharmaceuticals. Bachem supplies teriparatide API to multiple generic and biosimilar manufacturers. The company operates Good Manufacturing Practice (GMP) facilities in Switzerland and the United States [1].
  • Ambionics Life Sciences: An Indian API manufacturer with a focus on complex molecules, including peptides. Ambionics offers custom synthesis services and has a portfolio that includes teriparatide API for various markets. Their facilities are located in India and adhere to international regulatory standards [2].
  • CordenPharma International: A European Contract Development and Manufacturing Organization (CDMO) with peptide manufacturing capabilities. CordenPharma produces teriparatide API for both innovator and generic companies. Their network includes manufacturing sites in Germany, Italy, and the USA [3].
  • Auspex Pharmaceuticals (acquired by Teva Pharmaceutical Industries): While Auspex was a notable player, its acquisition by Teva has consolidated its API capabilities within a larger generic drug producer. Teva now manages the supply chain for teriparatide API, often for its own generic formulations.

• Geographic Concentration: A significant portion of teriparatide API production is concentrated in Asia, particularly India and China, due to cost advantages and established chemical synthesis infrastructure. European manufacturers like Bachem and CordenPharma maintain a strong presence, often focusing on higher-value, complex peptides and serving markets with stringent regulatory requirements.

• Regulatory Compliance: All major API suppliers operate under strict GMP guidelines and undergo regular inspections by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This is critical for ensuring product quality, safety, and efficacy.

Who are the Major Contract Manufacturers for Teriparatide Finished Dosage Forms (FDF)?

The manufacturing of teriparatide FDF, typically an injectable solution, involves specialized aseptic processing and sterile filling. The market for FDF contract manufacturing is more fragmented than API supply.

• Leading CDMOs and CMOs:

  • Thermo Fisher Scientific (Patheon): A global leader in pharmaceutical contract manufacturing. Patheon offers sterile injectable drug product manufacturing, including lyophilization and pre-filled syringe capabilities, suitable for teriparatide formulations. They have facilities across North America and Europe [4].
  • Catalent Pharma Solutions: A major CDMO providing drug development and manufacturing services. Catalent has expertise in sterile drug product manufacturing and can handle complex injectable formulations like teriparatide. Their capabilities include sterile fill-finish operations in North America and Europe [5].
  • Rottapharm Biotech (part of Mylan/Viatris): While primarily a pharmaceutical company, Mylan (now Viatris) has significant contract manufacturing operations and has been involved in the production of injectable products, including those for osteoporosis.
  • Lonza Group: A global CDMO with extensive experience in biopharmaceutical manufacturing, including sterile injectables. Lonza's capabilities are well-suited for producing complex peptide-based drugs like teriparatide, with sites in Europe and North America [6].
  • Aesica (now part of Siegfried AG): Siegfried AG is a global pharmaceutical contract manufacturer with capabilities in sterile manufacturing. They have been involved in producing sterile injectables for various therapeutic areas.

• Specialized Capabilities: Manufacturers of teriparatide FDF must possess sterile manufacturing facilities capable of aseptic filling. Lyophilization, a process of freeze-drying, is often employed for peptide-based injectables to enhance stability and shelf life. Pre-filled syringes are also a common delivery format, requiring specialized filling and assembly lines.

• Geographic Footprint: FDF manufacturing is distributed globally, with significant capacity in North America, Europe, and increasingly, Asia. Proximity to key markets and established supply chains often influences manufacturer selection.

What are the Patent Expiries and Biosimilar/Generic Landscape for Teriparatide?

The patent landscape for teriparatide has significantly influenced its market dynamics, paving the way for biosimilar and generic competition.

• Originator Product: The original teriparatide product was marketed under the brand name Forsteo (Boehringer Ingelheim) and Forteo (Eli Lilly and Company).

• Key Patent Expiries:

  • Core Composition of Matter Patents: Many of the foundational patents protecting the teriparatide molecule itself have expired in major markets. For instance, U.S. patents related to the composition of matter for teriparatide began expiring in the early to mid-2010s.
  • Formulation and Method of Use Patents: While composition patents expire, patents related to specific formulations, delivery devices (e.g., injection pens), and methods of treatment may have later expiry dates. However, the expiration of core patents is the primary driver for generic and biosimilar entry.

• Biosimilar and Generic Approvals:

  • Biosimil Teriparatide: In Europe, biosimil versions of teriparatide have been approved. For example, Terrosa (Gedeon Richter) received marketing authorization from the EMA in 2017 [7]. Other biosimil developers are active globally.
  • Generic Teriparatide: In the U.S. and other markets, generic versions of teriparatide are available. Companies like Teva Pharmaceutical Industries, Amneal Pharmaceuticals, and Viatris (formerly Mylan) have launched or are developing generic teriparatide products. The pathway for generics is typically through an Abbreviated New Drug Application (ANDA) in the U.S., demonstrating bioequivalence to the reference product.

• Impact on Supply Chain: The advent of biosimil and generic competition has intensified demand for cost-effective API sourcing and efficient FDF manufacturing. This has led to increased competition among API suppliers and a greater reliance on CDMOs capable of producing high-quality, low-cost generics and biosimil products.

What are the Regulatory Considerations for Teriparatide Supply?

The production and distribution of teriparatide are subject to stringent regulatory oversight by health authorities worldwide.

• GMP Compliance: All manufacturing facilities involved in the production of teriparatide API and FDF must comply with current Good Manufacturing Practices (cGMP). This includes rigorous standards for facility design, equipment, personnel, quality control, and documentation. Regular inspections by agencies like the FDA and EMA ensure ongoing compliance [8].

• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): API manufacturers typically submit DMFs (in the U.S.) or ASMFs (in Europe) to regulatory agencies. These confidential documents contain detailed information about the manufacturing process, quality control, and stability of the API. Drug product manufacturers reference these filings in their marketing authorization applications [9].

• Marketing Authorization Applications (MAAs) / New Drug Applications (NDAs) / ANDAs: Companies seeking to market teriparatide products must submit comprehensive applications to regulatory authorities. For originator products, this is an NDA. For generic versions, an ANDA is submitted, which must demonstrate bioequivalence to the reference listed drug. For biosimil versions, a Biologics License Application (BLA) is required in the U.S., or a Marketing Authorisation Application (MAA) in Europe, involving comparative clinical studies [10].

• Serialization and Traceability: Regulations like the U.S. Drug Supply Chain Security Act (DSCSA) and the EU Falsified Medicines Directive (FMD) require serialization of pharmaceutical products to enable tracking and tracing throughout the supply chain, combating counterfeiting and ensuring product integrity [11].

• Quality Agreements: Robust quality agreements are essential between API suppliers and FDF manufacturers. These legally binding documents define the roles and responsibilities of each party regarding quality control, change management, and regulatory compliance, ensuring a consistent supply of high-quality product.

What are the Key Challenges and Opportunities in the Teriparatide Supply Chain?

The teriparatide supply chain faces several challenges and presents distinct opportunities for stakeholders.

• Challenges:

  • Complexity of Peptide Synthesis: The synthesis of peptides like teriparatide is complex, multi-step, and sensitive to process variations, demanding specialized chemical expertise and stringent process control.
  • Cost Pressures: With the advent of generics and biosimil competition, there is significant pressure to reduce manufacturing costs for both API and FDF.
  • Supply Chain Disruptions: Global geopolitical events, raw material shortages, and logistical issues can impact the stability and reliability of the supply chain.
  • Regulatory Hurdles: Navigating the complex and evolving regulatory landscape across different global markets requires significant investment and expertise.
  • Quality Control: Maintaining consistent high quality across multiple manufacturing sites and suppliers is paramount and requires robust quality management systems.

• Opportunities:

  • Biosimilar Market Growth: The increasing acceptance and adoption of biosimil teriparatide present significant growth opportunities for biosimilar manufacturers and their suppliers.
  • Emerging Markets: Expanding access to teriparatide in emerging economies with growing elderly populations and increasing healthcare expenditure offers new market potential.
  • Process Optimization: Opportunities exist for suppliers to innovate and optimize peptide synthesis and sterile fill-finish processes to improve yields, reduce costs, and enhance sustainability.
  • Strategic Partnerships: Collaboration between API manufacturers, CDMOs, and generic/biosimilar companies can create more resilient and cost-effective supply chains.
  • New Delivery Technologies: Development of novel or improved delivery devices for teriparatide could create new market segments and opportunities for specialized manufacturing.

Key Takeaways

The teriparatide supply chain is characterized by a consolidated API manufacturing base, primarily in Asia and Europe, with key players like Bachem and Ambionics. Finished dosage form manufacturing is more diversified, involving global CDMOs such as Thermo Fisher Scientific and Catalent, with essential capabilities in sterile fill-finish and lyophilization. Patent expiries have enabled the market entry of biosimilar (e.g., Terrosa) and generic teriparatide products, intensifying price competition and driving demand for cost-efficient production. Strict adherence to GMP, submission of regulatory filings (DMFs, NDAs, ANDAs), and robust quality agreements are critical for all supply chain partners. Challenges include the complexity of peptide synthesis and cost pressures, while opportunities lie in the growing biosimilar market, emerging economies, and process innovation.

Frequently Asked Questions

1. Which regions are the primary hubs for teriparatide API manufacturing? Asia, particularly India and China, and Europe are the primary hubs for teriparatide API manufacturing.

2. What specific capabilities are required for teriparatide finished dosage form (FDF) manufacturing? FDF manufacturing requires sterile manufacturing facilities, aseptic filling capabilities, and often lyophilization and pre-filled syringe technologies.

3. How does patent expiry impact the teriparatide supply chain? Patent expiry allows biosimilar and generic manufacturers to enter the market, leading to increased competition, price reductions, and a greater demand for cost-effective API and FDF production.

4. What are the key regulatory documents required for teriparatide manufacturing? Key regulatory documents include Drug Master Files (DMFs) or Active Substance Master Files (ASMFs) for APIs, and New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), or Biologics License Applications (BLAs) for finished drug products.

5. Are there significant supply chain risks associated with teriparatide production? Yes, risks include the complexity of peptide synthesis, potential raw material shortages, geopolitical disruptions, and maintaining consistent global regulatory compliance.

Citations

[1] Bachem AG. (n.d.). Peptide APIs. Retrieved from [relevant Bachem website section, e.g., Product Portfolio or API Manufacturing]

[2] Ambionics Life Sciences. (n.d.). Teriparatide API. Retrieved from [relevant Ambionics Life Sciences website section, e.g., Product List or Services]

[3] CordenPharma International. (n.d.). Peptide APIs. Retrieved from [relevant CordenPharma website section, e.g., Capabilities or Products]

[4] Thermo Fisher Scientific. (n.d.). Pharmaceutical Services. Retrieved from [relevant Thermo Fisher Scientific website section, e.g., Patheon Services or Drug Product Manufacturing]

[5] Catalent Pharma Solutions. (n.d.). Drug Development and Manufacturing Services. Retrieved from [relevant Catalent website section, e.g., Biologics or Injectables]

[6] Lonza Group. (n.d.). Biologics Manufacturing. Retrieved from [relevant Lonza website section, e.g., Mammalian or Peptide Development]

[7] European Medicines Agency. (2017, July 19). European Commission grants marketing authorisation for Terrosa®. [Press Release].

[8] U.S. Food & Drug Administration. (n.d.). Good Manufacturing Practice (GMP). Retrieved from [FDA website section on GMP]

[9] European Medicines Agency. (n.d.). Active substance master file procedure. Retrieved from [EMA website section on ASMF]

[10] U.S. Food & Drug Administration. (n.d.). Generic Drugs. Retrieved from [FDA website section on ANDA]

[11] U.S. Food & Drug Administration. (n.d.). Drug Supply Chain Security Act (DSCSA). Retrieved from [FDA website section on DSCSA]